The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model

Behavioural Brain Research

Volumn 287, Issue , 2015, Pages 96-99

  Puri, Vanita ^a   Wang, Xiaohai ^a   Vardigan, Joshua D ^a   Kuduk, Scott D ^a   Uslaner, Jason M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer's disease; Cognition; Muscarinic; Novel object recognition; Tg2576; Working memory

Indexed keywords

AMYLOID BETA PROTEIN; DONEPEZIL; MUSCARINIC M1 RECEPTOR AGONIST; PCQA; UNCLASSIFIED DRUG; 1-((4-CYANO-4-(PYRIDINE-2-YL)PIPERIDIN-1-YL)METHYL)-4-OXO-4H-QUINOLIZINE-3-CARBOXYLIC ACID; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; MUSCARINIC M1 RECEPTOR; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; QUINOLIZINE DERIVATIVE;

AGED; ALLOSTERISM; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; LEARNING DISORDER; LOW DRUG DOSE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; TRANSGENIC MOUSE; AGING; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; MEMORY DISORDERS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RECOGNITION;

AGING; ALZHEIMER DISEASE; ANIMALS; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; INDANS; MEMORY DISORDERS; MICE, TRANSGENIC; NOOTROPIC AGENTS; PIPERIDINES; QUINOLIZINES; RECEPTOR, MUSCARINIC M1; RECOGNITION (PSYCHOLOGY);

EID: 84926207820     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.03.029     Document Type: Article

References (32)

1. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
2. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1:345-347.
3. Golde T.E., Eckman C.B., Younkin S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim et Biophys Acta 2000, 1502:172-187.
4. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
5. Turon-Estrada A., Lopez-Pousa S., Gelada-Batlle E., Garre-Olmo J., Lozano-Gallego M., Hernandez-Ferrandiz M., et al. Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period. Rev de Neurol 2003, 36:421-424.
6. Birks J., Harvey R.J. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006, CD001190.
7. Vardigan J.D., Cannon C.E., Puri V., Dancho M., Koser A., Wittmann M. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 2014, 52:441-448.
8. Levey A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993, 52:441-448.
9. Matsui M., Yamada S., Oki T., Manabe T., Taketo M.M., Ehlert F.J. Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci 2004, 75:2971-2981.
10. Kuduk S.D., Chang R.K., Di Marco C.N., Pitts D.R., Greshock T.J., Ma L., et al. Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. J Med Chem 2011, 54:4773-4780.
11. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991, 11:3218-3226.
12. Ma L., Seager M.A., Wittmann M., Jacobson M., Bickel D., Burno M., et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A 2009, 106:15950-15955.
13. Chambon C., Wegener N., Gravius A., Danysz W. A new automated method to assess the rat recognition memory: validation of the method. Behav Brain Res 2011, 222:151-157.
14. Uslaner J.M., Eddins D., Puri V., Cannon C.E., Sutcliffe J., Chew C.S., et al. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology 2013, 225:21-30.
15. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (New York, NY) 1996, 274:99-102.
16. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related a beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56:965-973.
17. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
18. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999, 2:271-276.
19. King D.L., Arendash G.W., Crawford F., Sterk T., Menendez J., Mullan M.J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 1999, 103:145-162.
20. Pompl P.N., Mullan M.J., Bjugstad K., Arendash G.W. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. J Neurosci Methods 1999, 87:87-95.
21. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006, 199:265-273.
22. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science (New York, NY) 1992, 258:304-307.
23. Wolf B.A., Wertkin A.M., Jolly Y.C., Yasuda R.P., Wolfe B.B., Konrad R.J., et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 1995, 270:4916-4922.
24. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8:1051-1058.
25. Kurup P., Zhang Y., Xu J., Venkitaramani D.V., Haroutunian V., Greengard P., et al. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 2010, 30:5948-5957.
26. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
27. Cerpa W., Farias G.G., Godoy J.A., Fuenzalida M., Bonansco C., Inestrosa N.C. Wnt-5a occludes a beta oligomer-induced depression of glutamatergic transmission in hippocampal neurons. Mol Neurodegener 2010, 5:3.
28. Fernandez de Sevilla D., Buno W. The muscarinic long-term enhancement of NMDA and AMPA receptor-mediated transmission at Schaffer collateral synapses develop through different intracellular mechanisms. J Neurosci 2010, 30:11032-11042.
29. Jones C.K., Brady A.E., Davis A.A., Xiang Z., Bubser M., Tantawy M.N., et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008, 28:10422-10433.
30. Lebois E.P., Bridges T.M., Lewis L.M., Dawson E.S., Kane A.S., Xiang Z. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci 2009, 1:104-121.
31. Marino M.J., Rouse S.T., Levey A.I., Potter L.T., Conn P.J. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A 1998, 95:11465-11470.
32. Shirey J.K., Brady A.E., Jones P.J., Davis A.A., Bridges T.M., Kennedy J.P., et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 2009, 29:14271-14286.